Search

Your search keyword '"Logallo, Nicola"' showing total 274 results
Start Over Author "Logallo, Nicola"
274 results on '"Logallo, Nicola"'

4. Comparison of diffusion weighted imaging b0 with T2*-weighted gradient echo or susceptibility weighted imaging for intracranial hemorrhage detection after reperfusion therapy for ischemic stroke

Author

Luijten, Sven P. R., van der Ende, Nadinda A. M., Cornelissen, Sandra A. P., Kluijtmans, Leo, van Hattem, Antonius, Lycklama a Nijeholt, Geert, Postma, Alida A., Bokkers, Reinoud P. H., Thomassen, Lars, Waje-Andreassen, Ulrike, Logallo, Nicola, Bracard, Serge, Gory, Benjamin, Roozenbeek, Bob, Dippel, Diederik W. J., and van der Lugt, Aad

Published
2023
Full Text
View/download PDF

7. Interobserver Agreement on Intracranial Hemorrhage on Magnetic Resonance Imaging in Patients With Ischemic Stroke

Author

van der Ende, Nadinda A.M., Luijten, Sven P.R., Kluijtmans, Leo, Postma, Alida A., Cornelissen, Sandra A., van Hattem, Antonius M.G., Lycklama à Nijeholt, Geert J., Bokkers, Reinoud P.H., Thomassen, Lars, Waje-Andreassen, Ulrike, Logallo, Nicola, Bracard, Serge, Gory, Benjamin, Roozenbeek, Bob, Dippel, Diederik W.J., and van der Lugt, Aad

Published
2023
Full Text
View/download PDF

16. Tenecteplase versus alteplase for management of acute ischaemic stroke (NOR-TEST): a phase 3, randomised, open-label, blinded endpoint trial

Author

Logallo, Nicola, Novotny, Vojtech, Assmus, Jörg, Kvistad, Christopher E, Alteheld, Lars, Rønning, Ole Morten, Thommessen, Bente, Amthor, Karl-Friedrich, Ihle-Hansen, Hege, Kurz, Martin, Tobro, Håkon, Kaur, Kamaljit, Stankiewicz, Magdalena, Carlsson, Maria, Morsund, Åse, Idicula, Titto, Aamodt, Anne Hege, Lund, Christian, Næss, Halvor, Waje-Andreassen, Ulrike, and Thomassen, Lars

Published
2017
Full Text
View/download PDF

22. Comparison of diffusion weighted imaging b0 with T2*-weighted gradient echo or susceptibility weighted imaging for intracranial hemorrhage detection after reperfusion therapy for ischemic stroke

Author

Luijten, Sven P.R., van der Ende, Nadinda A.M., Cornelissen, Sandra A.P., Kluijtmans, Leo, van Hattem, Antonius, Lycklama a Nijeholt, Geert, Postma, Alida A., Bokkers, Reinoud P.H., Thomassen, Lars, Waje-Andreassen, Ulrike, Logallo, Nicola, Bracard, Serge, Gory, Benjamin, Roozenbeek, Bob, Dippel, Diederik W.J., van der Lugt, Aad, Luijten, Sven P.R., van der Ende, Nadinda A.M., Cornelissen, Sandra A.P., Kluijtmans, Leo, van Hattem, Antonius, Lycklama a Nijeholt, Geert, Postma, Alida A., Bokkers, Reinoud P.H., Thomassen, Lars, Waje-Andreassen, Ulrike, Logallo, Nicola, Bracard, Serge, Gory, Benjamin, Roozenbeek, Bob, Dippel, Diederik W.J., and van der Lugt, Aad

Abstract

Purpose: Diffusion-weighted imaging (DWI) b0 may be able to substitute T2*-weighted gradient echo (GRE) or susceptibility-weighted imaging (SWI) in case of comparable detection of intracranial hemorrhage (ICH), thereby reducing MRI examination time. We evaluated the diagnostic accuracy of DWI b0 compared to T2*GRE or SWI for detection of ICH after reperfusion therapy for ischemic stroke. Methods: We pooled 300 follow-up MRI scans acquired within 1 week after reperfusion therapy. Six neuroradiologists each rated DWI images (b0 and b1000; b0 as index test) of 100 patients and, after a minimum of 4 weeks, T2*GRE or SWI images (reference standard) paired with DWI images of the same patients. Readers assessed the presence of ICH (yes/no) and type of ICH according to the Heidelberg Bleeding Classification. We determined the sensitivity and specificity of DWI b0 for detection of any ICH, and the sensitivity for detection of hemorrhagic infarction (HI1 & HI2) and parenchymal hematoma (PH1 & PH2). Results: We analyzed 277 scans of ischemic stroke patients with complete image series and sufficient image quality (median age 65 years [interquartile range, 54–75], 158 [57%] men). For detection of any ICH on DWI b0, the sensitivity was 62% (95% CI: 50–76) and specificity 96% (95% CI: 93–99). The sensitivity of DWI b0 was 52% (95% CI: 28–68) for detection of hemorrhagic infarction and 84% (95% CI: 70–92) for parenchymal hematoma. Conclusion: DWI b0 is inferior for detection of ICH compared to T2*GRE/SWI, especially for smaller and more subtle hemorrhages. Follow-up MRI protocols should include T2*GRE/SWI for detection of ICH after reperfusion therapy.

Published
2023

35. Sex differences in the Norwegian Tenecteplase Trial (NOR‐TEST)

Author

Ihle‐Hansen, Håkon, primary, Sandset, Else Charlotte, additional, Ihle‐Hansen, Hege, additional, Hagberg, Guri, additional, Thommessen, Bente, additional, Rønning, Ole Morten, additional, Kvistad, Christopher Elnan, additional, Novotny, Vojtech, additional, Næss, Halvor, additional, Waje‐Andreassen, Ulrike, additional, Thomassen, Lars, additional, and Logallo, Nicola, additional

Published
2021
Full Text
View/download PDF

45. Sex differences in the Norwegian Tenecteplase Trial (NOR‐TEST).

Author

Ihle‐Hansen, Håkon, Sandset, Else Charlotte, Ihle‐Hansen, Hege, Hagberg, Guri, Thommessen, Bente, Rønning, Ole Morten, Kvistad, Christopher Elnan, Novotny, Vojtech, Næss, Halvor, Waje‐Andreassen, Ulrike, Thomassen, Lars, and Logallo, Nicola

Subjects
STROKE, ISCHEMIC stroke, HDL cholesterol, CARDIOVASCULAR diseases risk factors, INTRACRANIAL hemorrhage, TREATMENT effectiveness
Abstract

Background and purpose: Sex differences in acute ischemic stroke is of increasing interest in the era of precision medicine. We aimed to explore sex disparities in baseline characteristics, management and outcomes in patients treated with intravenous thrombolysis included in the Norwegian Tenecteplase trial (NOR‐TEST). Methods: NOR‐TEST was an open‐label, randomized, blinded endpoint trial, performed from 2012 to 2016, comparing treatment with tenecteplase to treatment with alteplase within 4.5 h after acute ischemic stroke symptom onset. Sex differences at baseline, treatment and outcomes were compared using multivariable logistic regression models. Heterogeneity in treatment was evaluated by including an interaction term in the model. Results: Of 1100 patients enrolled, 40% were women, and in patients aged >80 years, the proportion of women was greater than men (19% vs. 14%; p = 0.02). Women had a lower burden of cardiovascular risk factors, such as diabetes mellitus (11% vs. 15%; p = 0.05) and a higher mean high‐density lipoprotein cholesterol level (1.7 ± 0.6 mmol/L vs. 1.3 ± 0.4 mmol/L; p < 0.001), and a higher proportion of women had never smoked (45% vs. 33%; p < 0.001) compared with men. While there was no sex difference in time from onset of symptoms to admission, door to needle time or in‐hospital workup, women were admitted with more severe stroke (National Institutes of Health Stroke Scale [NIHSS] score 6.2 ± 5.6 vs. 5.3 ± 5.1; p = 0.01). Stroke mimic diagnosis was more common in women (21% vs. 15%; p = 0.01). There were no significant sex differences in clinical outcome, measured by the NIHSS, the modified Rankin Scale, intracranial hemorrhage and mortality. Conclusion: Women were underrepresented in number in NOR‐TEST. The included women had a lower cardiovascular risk factor burden and more severe strokes. [ABSTRACT FROM AUTHOR]

Published
2022
Full Text
View/download PDF

47. Endovascular treatment of carotid-cavernous fistulas in a medium-sized Scandinavian neurovascular center.

Author

Mørkve, Svein Harald, Wathle, Gaute Kjellevold, and Logallo, Nicola

Subjects
*SCOTOMA, *THERAPEUTIC embolization, *ENDOVASCULAR surgery, *VISUAL fields, *THERAPEUTIC complications
Abstract

PurposeMethodsResultsConclusionsCarotid-cavernous fistulas (CCFs) are treated almost exclusively by endovascular techniques, but the frequency of treatments is limited in smaller centers. We analyzed all CCFs treated in our hospital to determine if high-quality treatment of CCFs can be provided in a medium-volume neurovascular center.Retrospective quality-control cohort study.From 2005 to 2021, 28 CCF-treatments were performed in our hospital, all endovascular. Fourteen were direct and fourteen were indirect CCFs. All direct CCFs were treated using transarterial coil embolization, and in seven of these the ICA was preserved. All indirect CCFs were treated using transvenous coil embolization. Complete cure was achieved after one procedure in 24 (85.7%) patients, and in all patients (100%) after retreatments. All CCF-patients experienced significant improvement of symptoms after treatment and 79.2% were asymptomatic after 6–12 months. Two patients with direct CCFs were blind on their ipsilateral eye before treatment and remained so after treatment. Three patients had reduced vision or visual field defects ipsilateral to their indirect CCFs that normalized after treatment. One patient suffered a minor asymptomatic thromboembolic event during the treatment (3.6%), otherwise there were no complications to treatments.High-quality treatment of CCFs can be provided in a medium-volume neurovascular center. [ABSTRACT FROM AUTHOR]

Published
2025
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results